Compare Marsh & McLennan Companies, Inc. (MRSH) vs Philip Morris International Inc. (PM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Marsh & McLennan Companies, Inc. vs Philip Morris International Inc. — how do they compare? Marsh & McLennan Companies, Inc. trades at $176.51 (market cap $84.31B), while Philip Morris International Inc. trades at $200.2 (market cap $312.50B). The key difference: Philip Morris International Inc. is far larger — about 3.7× Marsh & McLennan Companies, Inc.'s market cap, and Philip Morris International Inc. pays the higher dividend (3.19%). Which is the better fit depends on your goals — on Pluang, investors hold Marsh & McLennan Companies, Inc. for 109 Days and Philip Morris International Inc. for 85 Days on average.
| MRSH | PM | |
|---|---|---|
Market Cap | $84.31B | $312.50B |
Volume | 3,948,947 | 5,517,172 |
Sector | Financials | Consumer Staples |
52-Week High | $207.02 | $200.50 |
52-Week Low | $157.32 | $144.33 |
Typical Hold Time | 109 Days | 85 Days |
Enterprise Value | $104.99B | $355.62B |
Dividend Yield | 2.24% | 3.19% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Marsh (MRSH) trades at $173.66, up 1.11% today, with a bullish technical signal despite mixed moving averages. The company shows strong fundamentals with consistent revenue growth from $20.7B in 2022 to $27.0B in 2025, and net income reaching $4.16B. Recent acquisition of Accel Holdings (October 2026) enhances its insurance advisory footprint. Valuation metrics include a P/E of 21.2 and ROE of 25.72%, indicating efficient capital use. Cash flow remains positive with $486M net inflow in 2025.
Outlook is cautiously optimistic with a consensus price target of $202.71 (17% upside), though 65% of analysts rate Hold. Risks include rising debt-to-asset ratio (35.43% in 2024) and potential margin pressure as net income margin dips to 14.24% in 2026. The stock's proximity to resistance at $174 requires monitoring for breakout confirmation.
Philip Morris International (PM) trades at $200.5, up 5.3% over 24 hours, with a bullish technical signal and strong earnings beats in Q1 and Q2 2026. The company shows robust fundamentals with 2025 revenue of $40.65B and net income of $11.35B, supported by a 67.48% gross margin. Recent news highlights expansion of smoke-free products like ZYN and IQOS, now over 40% of revenue, driving growth amid industry shifts.
Outlook is positive with analyst consensus at Buy (68%) and a $212.17 price target, though elevated P/E of 26.46 and regulatory risks in tobacco remain concerns. Earnings growth and smoke-free product adoption are key catalysts, but investors should monitor debt levels and competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Marsh & McLennan Companies, Inc.
Marsh & McLennan Companies Inc is a professional services firm that provides advice and solutions in the areas of risk, strategy, and human capital. The company operates through two main segments: risk and insurance services and consulting. In risk and insurance services, the firm offers services via Marsh (an insurance broker) and Guy Carpenter (a risk and reinsurance specialist). The consulting division comprises Mercer (a provider of human resource services) and Oliver Wyman (management and economic consultancy).
Read more on MRSH →About Philip Morris International Inc.
Philip Morris International is an international tobacco company with a product portfolio primarily consisting of cigarettes and reduced-risk products, including heat-not-burn, vapor and oral nicotine products, which are sold in markets outside the United States. The company diversified away from nicotine products with the acquisition of Vectura, a provider of innovative inhaled drug delivery solutions, in 2021.
Read more on PM →
